IntroductionCryoglobulinemia can be among the causes of sperm bad quality. But conventional examination algorithm for patients with idiopathic oligozoospermia makes no provision for cryoglobulin determination in blood serum.Materials and methodsWe examined 55 patients with idiopathic spermatogenesis disorder. Each patient had cryoglobulin determined in blood serum. For this purpose, optical density of the patient's blood serum before and after its 7–day cooling at a temperature of 4°C was compared. Type of cryoglobulins was established by the method evaluation of serum optic density in different periods of cooling incubation (before and after cooling) using the curves of temperature resistance for comparison. Patients with cryoglobulinemia underwent intracutaneous immunization with autoleukocytes separated from heparinized venous blood.ResultsCryoglobulins were revealed in 16 patients of all 55 examined (29.09%): in six patients’ cryoglobulins of second type; in nine – third type and in one patient – cryoglobulins of first type were detected. In a control group, which consisted of 50 men is blood – donors’ frequency of cryoglobulinemia was 2%.Pathogenetic connection between cryoglobulinemia and disturbances in sperm quality is also supported by the fact that after autoleukocyte immunization in patients who positively responded to cryoglobulinemia treatment (14 persons of 16 or 87.5%) spermogram was found to be improved. Thus, in 12 patient number of spermatozoa. In all patients progressive motility and precentage of normal forms increased with spermatoza concentration.ConclusionsIt is reasonable to include determination of cryoglobulins in blood serum for patients with idiopathic oligo– and zoospermia.

Sixty one patients with a significant disturbance of tolerance to the thyroid antigens in the absence of disturbance of the thyroid function were involved in the research. Twenty two patients with chronic hepatitis C, genotype 1 HCV, receiving antiviral therapy, were also included in the research. Patients were immunized intracutaneously with autoleukocytes for autoimmune process inhibition. After single immunization with autoleukocytes decrease in the level of antibodies against the thyroid antigens was observed in all patients. In some patients without chronic hepatitis C the levels of thyroperoxidase and thyroglobulin antibodies decreased by 50% and more (33.33% and 20.51%, respectively). In patients with ChHC these indices were considerably lower, and the duration of the achieved effect was shorter. However, immunization inhibited activity of immune process in patients with ChHC due to interferon therapy. The suggested method enables to decrease the threat for thyroiditis development even in patients with chronic hepatitis C during antiviral therapy.

No abstract

No abstract